Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 7/20 | 0.36 |
| ▸ | CACNA2D1 | P54289 | 11/20 | 0.34 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.33 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | NR1I2 | O75469 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14048967 | 0.85 | CACNA2D1 (0.31) | CACNA2D1 | |
| SCHEMBL2878267 | 0.81 | ALDH1A1 (0.45) | OPRM1CACNA2D1ALDH1A1L3MBTL1 | |
| SCHEMBL2878269 | 0.81 | ALDH1A1 (0.45) | OPRM1CACNA2D1ALDH1A1L3MBTL1 | |
| SCHEMBL14048964 | 0.81 | NR1I2 (0.35) | OPRM1CHRM2CHRM3NR1I2 | |
| SCHEMBL5031700 | 0.79 | ALDH1A1 (0.40) | OPRM1CACNA2D1ALDH1A1POLB | |
| SCHEMBL5031698 | 0.79 | ALDH1A1 (0.40) | OPRM1CACNA2D1ALDH1A1POLB | |
| SCHEMBL12949686 | 0.75 | NR1I2 (0.39) | OPRM1CHRM2CHRM3ALDH1A1LMNA | |
| Hydrochloric Acid SCHEMBL16004727 | 0.74 | OPRM1 (0.40) | OPRM1CACNA2D1 | |
| Hydrochloric Acid SCHEMBL16004726 | 0.74 | OPRM1 (0.34) | OPRM1CACNA2D1NR1I2 | |
| SCHEMBL2431371 | 0.72 | ALDH1A1 (0.44) | ALDH1A1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080269481-A1 | Compounds and methods for the treatment or prevention of Flavivirus infections | VIROCHEM PHARMA INC. (CA) | 2008-10-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080269481-A1 | Compounds and methods for the treatment or prevention of Flavivirus infections | ZC3HAV1, ZYX, ZFX | OPRM1 4348/4885CACNA2D1 4753/4885CHRM2 4880/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.